Professor of Medicine, University Iowa College of Medicine
Hematology
Dr. Raymond J. Hohl, MD
|
|
Give Review
Doctor Raymond J. Hohl, MD practices Hematology. He attended Rush Medical College. He received awards:"Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Raymond Hohl is a published doctor and has 101 publications published. The lastest was: 'Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.' He is registered with Medicare and accepts Medicare payments.
Publications
- 3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines.
- Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
- Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid Tumors.
- Drug Development (and Academic Medicine): Charting the Course Forward.
- Personalized medicine: through the looking glass of functional imaging.
- Quantitative determination of isopentenyl diphosphate in cultured mammalian Cells.
- Is there a future for prenyltransferase inhibitors in Cancer therapy?
- Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intraCellular quantification.
- Geranylgeranyl pyrophosphate stimulates PPAcxuR? expression and adipogenesis through the inhibition of osteoblast differentiation.
- A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.
- Pleiotropic Effects of a Schweinfurthin on Isoprenoid Homeostasis.
- The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation.
- Effects of Farnesyl Pyrophosphate Accumulation on Calvarial Osteoblast Differentiation.
- Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
- Geranylgeranyl diphosphate depletion inhibits breast Cancer cell migration.
- Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
- Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue.
- Erythropoietin stimulates Cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent m...
- Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic e...
- Phase I and pharmacokinetic study of erlotinib for solid Tumors in patients with hepatic or renal dysfunction: CALGB 60101.
- Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity.
- Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
- Erythropoietin receptor signal transduction requires protein geranylgeranylation.
- Regulation of fatty acid synthesis by farnesyl pyrophosphate.
- Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured Cells.
- Synthesis and activity of fluorescent isoprenoid pyrophosphate Analogues.
- Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic Cells.
- Phase II study of high-dose fish oil capsules for patients with Cancer-related cachexia.
- Isoprenoids: remarkable diversity of form and function.
- Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis.
- Monoterpene regulation of Ras and Ras-related protein expression.
- Isoprenoid pyrophosphate Analogues regulate expression of Ras-related proteins.
- Stereoselective synthesis of the 5'-hydroxy-5'-phosphonate derivatives of cytidine and cytosine arabinoside.
- Isoprenoids influence expression of Ras and Ras-related proteins.
- Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB.
- Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 Cells.
- Geranylgeranyl diphosphate synthase: an emerging therapeutic target.
- A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem Cell transplantation.
- Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid Leukemia cells.
- A differential pharmacokinetic Analysis of the erythropoietin receptor population in newborn and adult sheep.
- Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pat...
- Pharmacokinetic tracer kinetics Analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
- Lovastatin inhibits T-Cell antigen receptor signaling independent of its effects on ras.
- Modulation of RAS expression in human malignant Cells by dietary supplements.
- Prophylactic T Cell infusion after T Cell-depleted bone marrow transplantation in patients with refractory lymphoma.
- Therapeutic additions and possible deletions in oncology in 2011.
- Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin Cheverly.
- Monoterpenes as regulators of malignant Cell proliferation.
- Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-Cell-depleted graft.
- A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast Cancer: a phase II study.
- Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with Cancer.
- Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed Acute leukemias: a phase 1 clinical-laboratory corre...
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
- Change in erythropoietin pharmacokinetics following hematopoietic transplantation.
- Engraftment Syndrome in autologous bone marrow and peripheral stem cell transplantation.
- Vascular medicine: a look forward.
- Prophylactic reinfusion of T Cells for T Cell-depleted allogeneic bone marrow transplantation.
- Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment.
- Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
- Defenses against oxidation in human erythrocytes: role of glutathione reductase in the activation of glucose decarboxylation by hemolytic drugs.
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory Lymphomas.
- Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of Cellular geranylgeranylation.
- Structural Analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure.
- Fluorescent schweinfurthin B and F Analogs with anti-proliferative activity.
- Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma Cells.
- Synthesis and biological evaluation of a series of aromatic bisphosphonates.
- Biologically active biotin derivatives of schweinfurthin F.
- Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous Leukemia.
- Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma Cells.
- Quantitative determination of geranyl diphosphate levels in cultured human Cells.
- Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.
- Synthesis and biological activity of a fluorescent schweinfurthin Analogue.
- Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase.
- The intermediate enzymes of isoprenoid metabolism as antiCancer targets.
- Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
- Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.
- A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
- Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series.
- Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation.
- Anti-Cancer therapy: targeting the mevalonate pathway.
- Synthesis and biological activity of isoprenoid bisphosphonates.
- Lovastatin alters the isoprenoid biosynthetic pathway in Acute myelogenous leukemia cells in vivo.
- Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies.
- Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.
- Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic Leukemia: final report of Cancer and Leukemia Group B study 19901.
- Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with Cancer.
- Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside.
- 2-(Acyloxy)ethylphosphonate Analogues of prenyl pyrophosphates: synthesis and biological characterization.
- Phosphonate and bisphosphonate Analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase.
- Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids.
- Interaction of cytosine arabinoside and lovastatin in human Leukemia cells.
- Differential effects of monoterpenes and lovastatin on RAS processing.
- Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and Leukemia group B study 9473.
- Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
- Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-Cellulose microspheres prepared by spray drying.
- Phase II trial of edatrexate in patients with metastatic colorectal Cancer.
- Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional Cell carcinoma: CALGB 90207.
- Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
- Synergistic interaction of lovastatin and paclitaxel in human Cancer cells.
- A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Schools
Rush University
University of Chicago
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Blue Card PPO
- Capital Blue Cross
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Golden Rule
- Community Blue PPO
- Humana
- Medicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
Rush Medical College
Hospital
-
Penn State Milton S. Hershey Medical Center
Drug Facts
| NPI NUMBER | 1710975651 | |
| NPPES Provider LastName | HOHL | |
| NPPES Provider FirstName | RAYMOND | |
| NPPES Provider ZIPCode | 170332360 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 675.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 77.0 | |
| Percent Opioid Claims | 11.41 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710975651 |
| Last Name Of The Provider | HOHL |
| First Name Of The Provider | RAYMOND |
| View All |
Similar Doctors
|
|
Dr. Salah M. Almokadem, DO
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert W. Hamilton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Ehmann, MD |
|
|
Dr. Malcom Acon Laws, MD |
|
|
Dr. David F. Claxton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William A. Flood Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheldon Holder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeremy Klapper, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allan Lipton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Witold B. Rybka, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mhd Y. Al-Marrawi, MD |
|
|
Dr. Mithun V. Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie A. Campbell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward J. Gunther, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syed Rizvi, MD |